The pathogenesis of transthyretin tissue deposition: lessons from transgenic mice - PubMed (original) (raw)
. 2003 Aug:10 Suppl 1:2-6.
Affiliations
- PMID: 14640034
The pathogenesis of transthyretin tissue deposition: lessons from transgenic mice
Joel Buxbaum et al. Amyloid. 2003 Aug.
Abstract
Attempts to produce animal models of the human transthyretin deposition disorders have not been as successful as investigators would wish. While random genomic insertion of mutant and wild-type human transthyretin genes has, in some instances, produced tissue deposits consisting of the human protein, in no case has a model faithfully reproduced the neuropathic pathology seen in FAP patients. Examining all the available models it appears that overexpression of the human construct is required with a resultant high level of protein production, as measured by the serum concentration. Animals, homo- or heterozygous for a single copy of a naturally occurring mutant human gene, even a thermodynamically unstable allele (leu55pro), do not develop immunohistochemically detectable tissue deposits. If the endogenous murine gene is subjected to targeted disruption, a small proportion of animals will develop tissue deposits of the human protein late in life. The implication of this observation is that the murine protein may stabilize mixed tetramers containing both mutant human and wild-type murine monomers in a manner similar to that seen in humans with the Met119 variant. As in humans with FAP or FAC, parenchymal hepatic deposition of either fibrillar or non-fibrillar deposits is uncommon. When TTR concentrations are similar in liver and kidney extracts, kidneys show evidence of aggregate deposition while livers do not. At least one of the transgenic models shows that non-fibrillar deposits precede the appearance of Congophilic tissue deposition, a circumstance that has also been seen in early neuropathic lesions of FAP patients. While none of the current models is a precise replicant of the human disease, the tissue specificity of deposition, the relationship to age in some models, the apparent sequential nature of the form of the deposits, and the sensitivity to the presence or absence of other gene products all reflect properties shared with FAP, FAC and SSA. They thus represent experimental systems for exploring factors and generally approachable in intact humans and reasonable screening tools for the effectiveness of various therapeutic approaches.
Similar articles
- Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
Cardoso I, Saraiva MJ. Cardoso I, et al. FASEB J. 2006 Feb;20(2):234-9. doi: 10.1096/fj.05-4509com. FASEB J. 2006. PMID: 16449795 - Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy.
Koike H, Ando Y, Ueda M, Kawagashira Y, Iijima M, Fujitake J, Hayashi M, Yamamoto M, Mukai E, Nakamura T, Katsuno M, Hattori N, Sobue G. Koike H, et al. J Neurol Sci. 2009 Dec 15;287(1-2):178-84. doi: 10.1016/j.jns.2009.07.028. Epub 2009 Aug 25. J Neurol Sci. 2009. PMID: 19709674 - Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.
Bergström J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olofsson BO, Westermark P. Bergström J, et al. J Pathol. 2005 Jun;206(2):224-32. doi: 10.1002/path.1759. J Pathol. 2005. PMID: 15810051 - Cellular consequences of transthyretin deposition.
Saraiva MJ. Saraiva MJ. Amyloid. 2003 Aug;10 Suppl 1:13-6. Amyloid. 2003. PMID: 14640036 Review.
Cited by
- Age-dependent small fiber neuropathy: Mechanistic insights from animal models.
Taub DG, Woolf CJ. Taub DG, et al. Exp Neurol. 2024 Jul;377:114811. doi: 10.1016/j.expneurol.2024.114811. Epub 2024 May 7. Exp Neurol. 2024. PMID: 38723859 Review. - Molecular tweezers for lysine and arginine - powerful inhibitors of pathologic protein aggregation.
Schrader T, Bitan G, Klärner FG. Schrader T, et al. Chem Commun (Camb). 2016 Oct 15;52(76):11318-34. doi: 10.1039/c6cc04640a. Epub 2016 Aug 22. Chem Commun (Camb). 2016. PMID: 27546596 Free PMC article. - Characterization of heterozygous ATTR Tyr114Cys amyloidosis-specific induced pluripotent stem cells.
Ouchi K, Isono K, Ohya Y, Shiraki N, Tasaki M, Inomata Y, Ueda M, Era T, Kume S, Ando Y, Jono H. Ouchi K, et al. Heliyon. 2024 Jan 17;10(2):e24590. doi: 10.1016/j.heliyon.2024.e24590. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38312695 Free PMC article. - Contributions of Animal Models to the Mechanisms and Therapies of Transthyretin Amyloidosis.
Ibrahim RB, Liu YT, Yeh SY, Tsai JW. Ibrahim RB, et al. Front Physiol. 2019 Apr 2;10:338. doi: 10.3389/fphys.2019.00338. eCollection 2019. Front Physiol. 2019. PMID: 31001136 Free PMC article. Review. - ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein.
Chen JJ, Genereux JC, Qu S, Hulleman JD, Shoulders MD, Wiseman RL. Chen JJ, et al. Chem Biol. 2014 Nov 20;21(11):1564-74. doi: 10.1016/j.chembiol.2014.09.009. Epub 2014 Oct 23. Chem Biol. 2014. PMID: 25444553 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous